Bayer clinches Monsanto deal with improved $66 billion bid
NEW YORK/FRANKFURT (Reuters) – German drugs and crop-chemicals company Bayer has won over US seeds firm Monsanto with an improved takeover offer of $66 billion including debt, ending months of wrangling after increasing its bid for a third time.
The $128-a-share deal announced on Wednesday, up from Bayer’s previous offer of $127.50 a share, is the biggest of the year so far and the largest cash bid on record.
The transaction will create a company commanding more than a quarter of the combined world market for seeds and pesticides in a fast-consolidating farm-supplies industry.
However, competition authorities are likely to scrutinize the tie-up closely, and some of Bayer’s own shareholders have been critical of a takeover plan, which they say is too expensive and risks neglecting the company’s pharmaceutical business.
“Bayer’s competitors are merging, so not doing this deal would mean having a competitive disadvantage,” said Markus Manns, a fund manager at Union Investment, one of Bayer’s top 12 investors, according to Thomson Reuters data.
Few people had expected a deal to be agreed to at less than $130 a share, he said, adding that there were regulatory risks, and the acquisition would also leave Bayer with less scope to invest in health care, where rivals are consolidating too.
The transaction includes a breakup fee of $2b. that Bayer will pay to Monsanto should it fail to get regulatory clearance. Bayer expects the deal to close by the end of 2017.
Baader Helevea Equity Research analyst Jacob Thrane, who has a “sell” rating on Bayer shares, said the German company was paying 16.1 times Monsanto’s forecast core earnings for 2017, more than the 15.5 times ChemChina agreed to pay for Swiss crop-chemicals firm Syngenta last year.
There was uncertainty over what the combined company would look like, he said, as regulators might demand asset sales.
Some analysts said the deal could face a rough ride from US politicians opposed to a key supplier of US agriculture falling into foreign hands and from farmers concerned a reduction in competition could lead to higher prices.
Bayer said it needed approval from antitrust authorities in 30 jurisdictions, but its initial feedback from both regulators and politicians was encouraging.
The German firm said it expects the deal to boost core earnings per share in the first full year following completion and by a double-digit percentage in the third year. It is targeting $1.2b. in annual cost synergies and $300 million in sales synergies after three years.
ONE-STOP SHOP
Bayer’s move to combine its crop-chemicals business, the world’s second largest after Syngenta, with Monsanto’s industry leading seeds business, is the latest in a series of major tie-ups in the agrochemicals sector.
The German company is aiming to create a one-stop shop for seeds, crop chemicals and computer-aided services to farmers.
That was also the idea behind Monsanto’s swoop on Syngenta last year, which the Swiss company fended off, only to agree later to a takeover by China’s stateowned ChemChina.
Elsewhere, US chemicals giants Dow Chemical and DuPont plan to merge and later spin off their respective seeds and crop-chemicals operations into a major agribusiness.
“The combined business will be ideally suited to cater to the requirements of farmers... because we have equal and meaningful strength in both crop protection, seeds and traits, and digital and analytical tools,” Bayer chief executive Werner Baumann said on a call with analysts.
The deal will be the largest ever involving a German buyer, beating Daimler’s tieup with Chrysler in 1998, which valued the US carmaker at more than $40b. It will also be the largest all-cash transaction on record, ahead of brewer InBev’s $60.4b. offer for Anheuser-Busch in 2008.
Bayer said it was offering a 44 percent premium to Monsanto’s share price on May 9, the day before it made its first written proposal.
It plans to raise $19b. to help fund the deal by issuing convertible bonds and new shares to its existing shareholders.
It said BofA Merrill Lynch, Credit Suisse, Goldman Sachs, HSBC and J.P. Morgan had committed to providing $57b. of bridge financing and that it was targeting an investment-grade credit rating after completion of the deal.
Bayer and Monsanto were in talks about a possible tie-up as early as March, which culminated in Bayer’s initial $122-pershare proposal in May.
Antitrust experts have said regulators will likely demand the sale of some soybean-, cotton- and canola-seed assets as a condition for approving the deal.